Deliver logo
Program Overview
The Asia Pharma R&D Leaders Summit 2019 ( APRDL 2019 ) will bring in fresh perspectives and scientific advancement on emerging therapeutic areas in Oncology, Immuno-Oncology, CAR-T & TCR Cell Therapy, neurodegenerative diseases & diabetes which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, targeting discovery, drugging the undruggable, promoting China innovation, medicinal chemistry outsourcing, AI innovation in pharma, manufacturing and process R&D, supply chain, commercialization, licensing collaboration, co-development opportunities, risk management approaches, outsourcing strategies, precision medicine and immune-oncology, regulatory issues and MAH systems, IP management and latest progress on revolution in future cancer treatment, biomarker research, safety data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2019 – the most premier pharma R&D event in China with Global perspectives:

Brainstorm with over 70 speakers and estimation to bring over 350 Global pharma R&D professionals, With this in mind, “ Asia Pharma R&D Leaders 2019 “ summit themes will cover:

-- Recent Trends & Development Opportunities of AI in Drug Discovery and Development
-- Strategic Challenges and Future Priorities of Next Generation CAR-T & TCR Cell Therapy Development
-- The Next Wave: Development of Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
-- Developing the Next Generation CAR-T & TCR Cell Immunotherapies -- CAR T-Cell Therapies in Glioblastoma & CAR T for Lymphoma and beyond
-- Clinical Data from China -- CAR T-Cell Therapy Achieves breakthrough Clinical Trial in China
-- Establish a Robust Supply Chain & Manufacturing Strategies to Deliver Personalized Cell Therapy
-- Personalized Anticancer Drug Discovery & Development in Asia
-- Novel Paradigms for Academic/Industry Synergistic Innovation Mechanism & Open Innovation Model
-- “ Undruggable ’ no more! -- Inhibiting KAT6A (MOZ) – A New Approach to Treating Cancer & Collaboration Opportunities
-- Opportunities for Medicinal Chemistry Outsourcing in China
-- Growth in Quality of Innovation – A Perspective about Drug Discovery in China
-- Revolution in Future Cancer Treatment and How Will it Scale over the Next 10 Years
-- KEYTRUDA®(Pembrolizumab) for the Treatment of Multiple Types of Cancer – Utilize Asia and China as an important source of Innovation
-- Advancing Immune Oncology in China – How best to address important unmet needs in China with an integrated global and local clinical
-- Promoting China Innovation – R&D Collaboration and Partnership
-- Automating CAR-T cell Commercial Manufacturing: Technologies Innovation and Collaboration
-- Novel Technologies and Approaches for Drug Discovery
-- Perceiving the Role and Importance of China for Global Drug Development -- Opportunities for Innovation
-- Government initiatives in China 13th 5 years’ plan benefit for your research projects in China
-- Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
-- Precision Medicine & Immuno-Oncology Therapy Development in Asia
-- Develop new business models in 2018 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
-- Lay foundations for effective partnership with top CROs, Biotech and Academia
-- Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia
-- Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process
-- Enhance your competitive edge by Establishing Industry-University-Institute Cooperation to Diversify Risks and Achieve R&D Productivity
-- Towards First-in-Class Anticancer Drugs With New Mechanism of Action
-- Primary and Secondary Mechanisms of Resistance to Anti-CD19 CAR T cell Therapy in NHL
-- Precision Immunotherapy: CAR T-Cell Therapy for Multiple Myeloma -- The Development Story of LCAR-B38M
-- Stage Appropriate CAR T Manufacturing and How to Plan a Facility for It

On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests And the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and cozy, guided 1-on-1 networking sessions for all professionals and management who are working for the pharmaceutical R&D Industry.
Asia Pharma R&D Leaders Summit 2019  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© Asia Pharma R&D Leaders Summit 2019 – All rights reserved